Regorafenib – LuciRegor

What it treats:

Regorafenib inhibits several kinases, including:

VEGFR1–3 (vascular endothelial growth factor receptors) → blocks angiogenesis.

PDGFR & FGFR → disrupts tumor stroma and blood supply.

KIT, RET, RAF → interferes with cancer cell signaling and growth.

Metastatic Colorectal Cancer (mCRC)

For adults whose disease has progressed after standard chemotherapy (e.g., fluoropyrimidine, oxaliplatin, irinotecan) and targeted therapies.

Gastrointestinal Stromal Tumors (GIST)

For patients who have failed or are intolerant to imatinib and sunitinib.

Hepatocellular Carcinoma (HCC)

For patients previously treated with sorafenib.